MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)

被引：72
|
作者：
Toffoli, G [1 ]
Veronesi, A
Boiocchi, M
Crivellari, D
机构：
[1] Natl Canc Inst, Ctr Riferimento Oncol, Div Expt Oncol 1, Aviano, PN, Italy
[2] Natl Canc Inst, Ctr Riferimento Oncol, Div Med Oncol C, Aviano, PN, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷 / 03期
关键词：
D O I：
10.1023/A:1008337900349
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：373 / 374
页数：2
相关论文
共 50 条
  • [1] Hepatic toxicity during adjuvant cyclophosphamide, methotrexate and 5-Fluorouracil (CMF) in breast cancer
    Noberasco, C
    Peruzzotti, G
    Colleoni, M
    Nole, F
    deBraud, F
    Martinelli, G
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 1998, 9 : 7 - 7
  • [2] Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil
    Colleoni, M
    Price, KN
    Castiglione-Gertsch, M
    Gelber, RD
    Coates, AS
    Goldhirsch, A
    LANCET, 1999, 354 (9173): : 130 - 131
  • [3] ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE, METHOTREXATE AND FLUOROURACIL (CMF) IN EARLY BREAST-CANCER - MECHANISMS OF ACTION
    PADMANABHAN, N
    HOWELL, A
    RUBENS, RD
    BRITISH JOURNAL OF CANCER, 1986, 53 (03) : 431 - 432
  • [4] Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer - Is it cost-effective ?
    Norum, J
    ACTA ONCOLOGICA, 2000, 39 (01) : 33 - 39
  • [5] CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH CYCLOPHOSPHAMIDE METHOTREXATE AND FLUOROURACIL (CMF) FOR BREAST-CANCER
    HOWELL, A
    BUSH, H
    GEORGE, WD
    HOWAT, JMT
    CROWTHER, D
    SELLWOOD, RA
    RUBENS, RD
    HAYWARD, JL
    BULBROOK, RD
    FENTIMAN, IS
    CHAUDARY, M
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 253 - 253
  • [6] Adjuvant CMF (cyclophosphamide, methotrexate, fluorouracil) in breast cancer. Is it cost-effective?
    Norum, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S229 - S229
  • [7] 5FU (5 fluorouracil) infusion duration and toxicity during CMF (cyclophosphamide, methotrexate, 5 fluorouracil) administration in adjuvant setting of breast cancer
    Capobianco, Alba M.
    Tartarone, Alfredo
    Coccaro, Mariarosa
    Di Leo, Pasquale
    Bochicchio, Annamaria
    Ardito, Raffaele
    Rionero, Crob
    ANNALS OF ONCOLOGY, 2006, 17 : 109 - 109
  • [8] Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer
    Poole, Christopher J.
    Earl, Helena M.
    Hiller, Louise
    Dunn, Janet A.
    Bathers, Sarah
    Grieve, Robert J.
    Spooner, David A.
    Agrawal, Rajiv K.
    Fernando, Indrajit N.
    Brunt, A. Murray
    O'Reilly, Susan M.
    Crawford, S. Michael
    Rea, Daniel W.
    Simmonds, Peter
    Mansi, Janine L.
    Stanley, Andrew
    Harvey, Peter
    McAdam, Karen
    Foster, Liz
    Leonard, Robert C. F.
    Twelves, Christopher J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (18): : 1851 - 1862
  • [9] Comparison of CVF (Cyclophosphamide plus Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide plus Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer
    Gwak, Geumhee
    Park, Kyeongmee
    Shin, Eunah
    Han, Sehwan
    Kim, Ji-Young
    Kim, Hongyong
    Kim, Young Duk
    Kim, Hong Ju
    Kim, Ki Whan
    Bae, Byung Noe
    Yang, Keun Ho
    Cho, Hyunjin
    Park, Sung-Jin
    JOURNAL OF BREAST CANCER, 2011, 14 (03) : 223 - 228
  • [10] Pharmacogenetics in cancer chemotherapy:: 677C→T methylenetetra-hydrofolate reductase (MTHFR) gene polymorphism and toxicity after cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Toffoli, G
    Crivellari, D
    Sartor, F
    Magri, MD
    Tolusso, B
    Scuderi, C
    Boiocchi, M
    Veronesi, A
    CLINICAL CANCER RESEARCH, 2000, 6 : 4555S - 4555S
12345